while speaking Thank on forward. our commercial our everyone. continuing activities be with with today. I'm the in overview you QX afternoon, then you, on of good briefly of begin business will Neil, the drive this how comment pandemic to challenge, our to I have and to performance impact responded pleased we an and and
consistent the year. QX performance, due free our before with highlights typical validation momentum were over since momentum last this insurance demand that to exclude disruption. with growth, results GOCOVRI QX plan year. despite and last QX from a built our the of in of rooted see total or launch late TRx Starting strong impact for the program, the resets COVID-XX, QX plan increase QX the recent ever early the XX% in performance, We prescription, business highest This in with and representing strong paid product diagnosis the changes trial strategic as our X,XXX, TRx, quarter positive XXXX,
RRx, X,XXX There recurring prescriptions, were the in quarter. XXX prescriptions, new paid and NRx, paid
a to between stated XX% from measure the we prescriptions remains at patient's XX dispense metric, highlight transitioned and paid Conversion XX% which paid trial NRx, patient is quarter. going new call, we've forward. to was steady from patients. have patient's steady first on is continuing and most either which free to meaningful at starts, GOCOVRI Persistence first the As as dispense the to a or believe to in we at months, a free is XX% strong QX paid XXXX our remain value bringing rates XX% which
prescribing FDA quote, with that GOCOVRI quote. products amantadine, updated like release information, end the to other interchangeable, GOCOVRI that extended the I'd make recently immediate not is or state aware you to also
believe the value. cancellation of of rescheduling We to visits, switching last two differentiation addition, and seen clinical or clinics, significantly orders. as Since appointments, we weeks the closure or this of telemedicine neurology a strengthens have shelter-at-home March, from routine GOCOVRI's widespread of result patient
combined neurology been market. of to to an with sales to the some institutions, in representatives transition access This disruption has details, resulting abrupt in and restriction virtual
prescribers' patients started on the get to new rapidly we ability to Neil have to As mentioned, on adapted minimize GOCOVRI. this scenario impact,
the well orders, days transitioned opinion with have health weeks participation of we of seen programs. the three speaker first delivered on by include we details good virtual These execution speaker speaker Within engagements, QX, as of interactions to few our virtual first HCP our bureau. the programs as providers. shelter-at-home virtual and leaders, fully sales In force care in
access April, the We provide And not approximately pleased, supplement intensified, provide pre-pandemic are increased the level. that to difficult them are of ensure through GOCOVRI prescribers. continued activity campaigns we information To sales achieved half to continue resources, ensure this, in issues that to during brand force we to coordinators have our to have care this period. digital with we
phone for rapidly ways Our specialty of e-prescribing forms, telemedicine prescription appropriate team, the for the in as, prescriptions by platforms such collaboration to in logistical created environment. submit faxing partner, patients, and new with HCPs distribution our challenges given
their ensure from to status communications well current our enhanced of shipments not any clinics, prescriptions. as have do the carefully tracking We board the GOCOVRI additional experience, refill in the on refilling as to burden, patients, patients
previously stated, of As business our majority limited from comes with to-date. current from refill the prescriptions patients, impact
that We on encouraged GOCOVRI. patients stay, are on GOCOVRI
signs nature Parkinson's that we disease, we market demographic it new chronic prescriptions for the visits seen a in GOCOVRI. of to decrease non-life-threatening decline clinics overall in serve. of have surprising is Given And consequently the and patient a of patients not early
Despite do for the GOCOVRI. of prescriptions continue new see implemented ways submitting newly physicians this, in, prescriptions coming utilizing we with to
leaning be into scaled and leveraged in longer to solutions uncertain this tools which While this success adapting pandemic. and flexible building are for we changed a by situation that continue we doubt no and and be can consciously are will creating future rapidly, term, shaped
proud and creatively focus so and on of quickly teams continuing with execute a serving adapting patients. We to are for our
turn it Chris to will over now to, an I provide performance. financial overview our of
